- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Dantrium® | F-368 | F-440 | Ryanodex®
dantrolene is an approved drug (FDA (1974))
Compound class: Synthetic organic
Comment: Dantrolene inhibits ryanodine receptor subtypes 1 and 3 (RyR1, and RyR3). The structure of dantrolene is commonly represented in the literature with charges, and it is this structure that we show here and link to in PubChem. However, the FDA and INN documents represent the compound without the charge.
Marketed formulations may contain dantrolene sodium (PubChem CID 6604100).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: dantrolene
|No information available.|
|Summary of Clinical Use|
|Dantrolene is a mucle relaxant used to treat patients suffering malignant hyperthermia crises, and may be used peri-operatively in these individuals to prevent crisis.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Dantrolene acts via the ryanodine receptor to decrease intracellular calcium concentration and suppress excitation-contraction coupling in skeletal muscle..|